- Home
- MEDP vs HALO Comparison
MEDP vs HALO Comparison
Compare MEDP & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MEDP
- HALO
- Stock Information
- Founded
- MEDP 1992
- HALO 1998
- Country
- MEDP United States
- HALO United States
- Employees
- MEDP N/A
- HALO N/A
- Industry
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MEDP Health Care
- HALO Health Care
- Exchange
- MEDP Nasdaq
- HALO Nasdaq
- Market Cap
- MEDP 8.5B
- HALO 7.4B
- IPO Year
- MEDP 2016
- HALO N/A
- Fundamental
- Price
- MEDP $321.50
- HALO $52.80
- Analyst Decision
- MEDP Hold
- HALO Buy
- Analyst Count
- MEDP 11
- HALO 9
- Target Price
- MEDP $338.90
- HALO $63.56
- AVG Volume (30 Days)
- MEDP 420.8K
- HALO 2.9M
- Earning Date
- MEDP 07-21-2025
- HALO 08-05-2025
- Dividend Yield
- MEDP N/A
- HALO N/A
- EPS Growth
- MEDP 33.36
- HALO 55.40
- EPS
- MEDP 13.09
- HALO 3.76
- Revenue
- MEDP $2,156,580,000.00
- HALO $1,084,306,000.00
- Revenue This Year
- MEDP $5.64
- HALO $25.77
- Revenue Next Year
- MEDP $3.32
- HALO $18.01
- P/E Ratio
- MEDP $24.56
- HALO $14.37
- Revenue Growth
- MEDP 9.87
- HALO 25.64
- 52 Week Low
- MEDP $250.05
- HALO $42.01
- 52 Week High
- MEDP $459.77
- HALO $70.51
- Technical
- Relative Strength Index (RSI)
- MEDP 65.60
- HALO 50.36
- Support Level
- MEDP $305.69
- HALO $51.06
- Resistance Level
- MEDP $314.58
- HALO $54.25
- Average True Range (ATR)
- MEDP 8.28
- HALO 1.22
- MACD
- MEDP 2.39
- HALO 0.23
- Stochastic Oscillator
- MEDP 98.59
- HALO 84.97
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical-device firms. It also offers ancillary services such as bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has over 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati and its operations are principally based in the US, but it also operates in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.